Allosterically potentiating ligands of nicotinic receptors as a treatment strategy for Alzheimer’s disease
- 21 August 2000
- journal article
- review article
- Published by Elsevier in Behavioural Brain Research
- Vol. 113 (1-2) , 199-206
- https://doi.org/10.1016/s0166-4328(00)00214-x
Abstract
No abstract availableKeywords
This publication has 50 references indexed in Scilit:
- Cholinesterase Inhibitors in the Treatment of Alzheimer??s DiseaseDrug Safety, 1998
- Mapping of a Binding Site for ATP within the Extracellular Region of the Torpedo Nicotinic Acetylcholine Receptor β-SubunitBiochemistry, 1997
- Nicotinic Receptor Function in SchizophreniaSchizophrenia Bulletin, 1996
- Epibatidine and ABT 418 reveal selective losses of α4β2 nicotinic receptors in Alzheimer brainsNeuroReport, 1995
- Physostigmine, galanthamine and codeine act as ‘noncompetitive nicotinic receptor agonists’ on clonal rat pheochromocytoma cellsEuropean Journal of Pharmacology: Molecular Pharmacology, 1995
- Kinetic Analysis of Regional (S)(-)11C-Nicotine Binding in Normal and Alzheimer Brains In Vivo Assessment Using Positron Emission TomographyAlzheimer Disease & Associated Disorders, 1995
- CNS Nicotinic ReceptorsCNS Drugs, 1994
- Structure of the high-affinity binding site for noncompetitive blockers of the acetylcholine receptor: [3H]chlorpromazine labels homologous residues in the .beta. and .delta. chainsBiochemistry, 1987
- Reduced number of [3H]nicotine and [3H]acetylcholine binding sites in the frontal cortex of Alzheimer brainsNeuroscience Letters, 1986
- Cholinergic underactivity in human memory disordersLife Sciences, 1978